Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
, in the Iressa Survival Evaluation in Lung Cancer (ISEL) trial, treatment with gefitinib did not result in a statistically significant improvement in overall survival time in comparison with BSC in patients who ...
gefitinib nor erlotinib conferred a survival advantage in previously untreated NSCLC when administered with two-drug chemotherapy regimens (gemcitabine plus cisplatin and paclitaxel plus carboplatin ...
(CALGB) initially evaluated the combination of induction carboplatin and paclitaxel for two cycles followed by low-dose weekly concurrent chemotherapy with RT. They found a median survival time of 15.1 ...
Sloan-Kettering Cancer Center. Open in new tab Table 5 Patients treated in placebo-controlled trials of gefitinib or erlotinib: survival improvement in patients who had never smoked Trial (year ...
that there is room for improvement . The standard chemotherapy for NSCLC involves one of a number of chemotherapy doublets that have been shown to improve survival when compared with single agents or best supportive ...
NSCLC Trial Assessing Combination Therapy (INTACT)-1 and INTACT-2, no survival or progression-free survival difference was reported in favor of the additions of gefitinib to platinum-based ...
for the treatment of advanced NSCLC: gefitinib and erlotinib. Of these, erlotinib has shown a significant improvement in median survival , quality of life, and related symptoms in an unselected population of advanced ...
polychemotherapy (cisplatin plus gemcitabine or carboplatin plus paclitaxel ) plus gefitinib over chemotherapy alone was reported [15, 16]. As observed for the other EGFR-TKI gefitinib , the combination of erlotinib ...
a plateau [1], and that any combination of a platinum and a third-generation agent will produce similar survival results, despite efforts to modify treatment toward further improving outcomes. This belief ...
, a vascular endothelial growth factor (VEGF)-targeted antibody, significantly improved overall survival compared with chemotherapy alone when administered in combination with paclitaxel and carboplatin ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!